Trials / Completed
CompletedNCT00251732
Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University of Arizona · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the role of pain modulation in GERD patients who fail to obtain clinical relief with standard dose (once daily) PPI. The study will compare the efficacy of 1) standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom resolution and health related quality of life in GERD patients who fail standard dose PPI and are randomly assigned to one of these three groups.
Detailed description
To evaluate the role of pain modulation in gastroesophageal reflux disease(GERD)patients who fail to obtain clinical relief with standard dose (once daily) proton pump inhibitor(PPI). The study will compare the efficacy; of 1)standard dose PPI plus low-dose tricyclic antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom resolution and health related quality of life in GERD patients who fail standard dose PPI and are randomly assigned to one of these three groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standard dose (once daily) PPI plus low-dose antidepressant | 20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA) |
| DRUG | Double dose PPI plus evening placebo | 20 mg. twice daily with a placebo |
| DRUG | Rabeprazole , placebo, placebo | 20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2005-11-10
- Last updated
- 2010-08-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00251732. Inclusion in this directory is not an endorsement.